Advocacy intelligence hub — real-time data for patient organizations
Voraxaze: FDA approved
Treatment of toxic (>1 micromole/liter) plasma methotrexate concentrations in patients with delayed methotrexate clearance due to impaired renal function.
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Voraxaze
(glucarpidase)Orphan drugBTG International Inc.
Carboxypeptidase [EPC]
12.1 Mechanism of Action Glucarpidase is a recombinant bacterial enzyme that hydrolyzes the carboxyl- terminal glutamate residue from folic acid and c...
Fusilev
(levoleucovorin)Orphan drugstandardAcrotech Biopharma LLC
12.1 Mechanism of Action High-Dose Methotrexate Therapy Levoleucovorin is the pharmacologically active isomer of 5-formyl tetrahydrofolic acid. Levole...
Leucovorin calcium
(Leucovorin)Orphan drugstandardImmunex Corporation
Antonio Omuro, MD, MD
Yale University
📍 STANFORD, CA
Richard E. Champlin, BS,MD
M.D. Anderson Cancer Center
Jennifer H Foster, MD
Baylor College of Medicine
Mikael Eriksson, MD PhD
Department of Oncology, Skåne University Hospital
Roderick Johnson, MD
Leeds General Infirmary
Suzanne Kincaid, CCRA
BTG International Inc.